Cardiff Oncology IncNASDAQ:CRDF
- LAST PRICE1.7300
- TODAY'S CHANGE (%)0.0100 (0.5814%)
- Bid / Lots1.6700/ 7
- Ask / Lots1.7800/ 11
- Open / Previous Close1.7600 / 1.7200
- Day Range
- 52 Week Range
- Volume65,278
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CRDF |
|---|---|---|
| 09:32 ET | 4265 | 1.77 |
| 09:37 ET | 4000 | 1.736 |
| 09:44 ET | 1100 | 1.745 |
| 09:46 ET | 470 | 1.76 |
| 09:57 ET | 1500 | 1.7401 |
| 10:02 ET | 150 | 1.7368 |
| 10:06 ET | 100 | 1.7449 |
| 10:08 ET | 100 | 1.7449 |
| 10:11 ET | 655 | 1.725 |
| 10:15 ET | 600 | 1.73 |
| 10:24 ET | 875 | 1.75 |
| 10:26 ET | 514 | 1.77 |
| 10:31 ET | 271 | 1.7536 |
| 10:44 ET | 3000 | 1.73 |
| 10:56 ET | 2693 | 1.73 |
| 11:00 ET | 400 | 1.73 |
| 11:02 ET | 100 | 1.735 |
| 11:05 ET | 100 | 1.74 |
| 11:38 ET | 100 | 1.74 |
| 11:52 ET | 241 | 1.71 |
| 11:56 ET | 2000 | 1.72 |
| 11:57 ET | 141 | 1.7121 |
| 12:03 ET | 100 | 1.725 |
| 12:06 ET | 5100 | 1.7201 |
| 12:15 ET | 100 | 1.725 |
| 01:08 ET | 2000 | 1.725 |
| 01:11 ET | 200 | 1.715 |
| 01:13 ET | 1000 | 1.73 |
| 01:15 ET | 300 | 1.72 |
| 01:26 ET | 100 | 1.72 |
| 01:31 ET | 1000 | 1.7299 |
| 01:40 ET | 400 | 1.73 |
| 01:47 ET | 1500 | 1.72 |
| 01:51 ET | 600 | 1.72 |
| 02:03 ET | 200 | 1.72 |
| 02:12 ET | 1000 | 1.71 |
| 02:16 ET | 1100 | 1.7 |
| 02:18 ET | 300 | 1.7 |
| 02:20 ET | 567 | 1.695 |
| 02:21 ET | 500 | 1.7 |
| 02:32 ET | 500 | 1.705 |
| 02:38 ET | 100 | 1.705 |
| 02:39 ET | 4050 | 1.705 |
| 02:41 ET | 7266 | 1.705 |
| 02:43 ET | 200 | 1.7 |
| 03:12 ET | 879 | 1.71 |
| 03:19 ET | 100 | 1.7099 |
| 03:32 ET | 1270 | 1.705 |
| 03:33 ET | 501 | 1.705 |
| 03:44 ET | 175 | 1.7068 |
| 03:46 ET | 2000 | 1.71 |
| 03:50 ET | 100 | 1.72 |
| 04:00 ET | 4253 | 1.73 |
Jan 19, 2023
Initiatives For Development of Gamma Delta T Cell Therapies Driven by Large Number of Clinical Trials, from 8:30AM ET on Thursday Jan 19, 2023 by PR Newswire
8:30AM ET on Thursday Jan 19, 2023 by PR Newswire
Jan 10, 2023
Cardiff Oncology to Present at B. Riley Securities' 3rd Annual Oncology Conference, from 8:00AM ET on Tuesday Jan 10, 2023 by PR Newswire
8:00AM ET on Tuesday Jan 10, 2023 by PR Newswire
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Cardiff Oncology Inc | 76.8M | -1.9x | --- |
Decibel Therapeutics Inc | 77.9M | -1.3x | --- |
Mustang Bio Inc | 75.7M | -0.9x | --- |
HCW Biologics Inc | 75.3M | -5.8x | --- |
IO Biotech Inc | 80.1M | -1.1x | --- |
Rezolute Inc | 73.5M | -1.1x | --- |
Company Information
Cardiff Oncology Inc. is a clinical-stage biotechnology company. The Company is focused on developing treatment for cancer patients. Its drug candidate onvansertib, is a polo-like kinase 1 (PLK1) adenosine triphosphate (ATP) competitive inhibitor with the combination of chemotherapy and targeted therapeutics. Its clinical trial includes TROV-054, CRDF-001 and TROV-053. TROV-054 is a Phase I b/2 open-label clinical trial of onvansertib in combination with FOLFIRI (folinic acid, fluorouracil, and irinotecan) and Avastin (bevacizumab). TROV-053 is a Phase II open-label clinical trial of onvansertib in combination with Zytiga (abiraterone acetate)/prednisone. CRDF-001 is a Phase 2 open-label multi-center clinical trial of onvansertib in combination with nanoliposomal irinotecan, leucovorin, and fluorouracil for second line treatment of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC).
Contact Information
- Headquarters
- 11055 Flintkote AveSAN DIEGO, CA, United States 92121-1220
- Phone
- 858-952-7570
- Fax
- 858-217-4768
Executives
- Independent Chairman of the Board
- Rodney Markin
- Chief Executive Officer
- Mark Erlander
- Chief Financial Officer
- James Levine
- Chief Operating Officer
- Vicki Kelemen
- Independent Director
- James Armitage
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $76.8M |
|---|---|
Revenue (TTM) | $391.0K |
Shares Outstanding | 44.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.64 |
EPS | $-0.93 |
Book Value | $3.35 |
P/E Ratio | -1.9x |
Price/Sales (TTM) | 196.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -10,239.39% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
